

BMJ Open Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study

Jawad Haider Butt ¹, Thomas Alexander Gerds,^{2,3} Morten Schou,⁴ Kristian Kragholm,⁵ Matthew Phelps,² Eva Havers-Borgersen,¹ Adelina Yafasova,¹ Gunnar Hilmar Gislason,^{2,6} Christian Torp-Pedersen,⁷ Lars Køber,¹ Emil Loldrup Fosbøl¹

To cite: Butt JH, Gerds TA, Schou M, *et al.* Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study. *BMJ Open* 2020;**10**:e044421. doi:10.1136/bmjopen-2020-044421

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-044421>).

Received 05 September 2020
Revised 02 November 2020
Accepted 09 November 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Jawad Haider Butt;
jawad_butt91@hotmail.com

ABSTRACT

Objective To investigate the association between recent statin exposure and risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 in Denmark.

Design and setting Observational cohort study using data from Danish nationwide registries.

Participants Patients diagnosed with COVID-19 from 22 February 2020 to 17 May 2020 were followed from date of diagnosis until outcome of interest, death or 17 May 2020.

Interventions Use of statins, defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis.

Primary and secondary outcome measures All-cause mortality, severe COVID-19 infection and the composite.

Results The study population comprised 4842 patients with COVID-19 (median age 54 years (25th–75th percentile, 40–72), 47.1% men), of whom 843 (17.4%) redeemed a prescription of statins. Patients with statin exposure were more often men and had a greater prevalence of comorbidities. The median follow-up was 44 days. After adjustment for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30-day standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%); SAR difference, –0.4% (–1.9% to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41); 30-day SAR, 13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%); SAR difference, 1.9% (–0.7% to 4.5%)), and the composite outcome of all-cause mortality or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 1.23); 30-day SAR, 17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%); SAR difference, 0.6% (–1.6% to 2.9%)). The results were consistent across subgroups of age, sex and presumed indication for statin therapy. Among patients with statin exposure, there was no difference between statin drug or treatment intensity with respect to outcomes.

Conclusions Recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection.

Strengths and limitations of this study

- The study was based on high-quality and complete data from nationwide administrative registries.
- The Danish healthcare system provides equal access to healthcare services for all residents regardless of socioeconomic or insurance status.
- The observational nature of this study precludes the assessment of cause–effect relationships.
- Residual confounding and confounding by indication cannot be excluded.

INTRODUCTION

The COVID-19 pandemic, caused by SARS-CoV-2, is an unprecedented threat to global health in recent time.¹ Governments worldwide have imposed comprehensive measures to prevent the rapid spread of SARS-CoV-2, including extensive societal lockdown and reorganisation of healthcare systems. Recently, an observational study demonstrated that in-hospital use of statins was associated with substantial improvement in survival among patients hospitalised with COVID-19.² Specifically, the authors reported a relative risk reduction of 42% in in-hospital mortality with statin therapy. This finding may be biased by patient selection, treatment indication and residual confounding and therefore merits further investigation.² In addition, a computer-based study suggested that rosuvastatin may be effective in the treatment of COVID-19 infection.³ However, other observational studies, including a meta-analysis, did not find any association between statins and improved outcomes in patients with COVID-19.^{4–6}

Several mechanisms by which statins may exert their potential beneficial effects have been proposed. First, the case fatality rate



with COVID-19 infection is substantially higher in patients with established cardiovascular disease and diabetes than those without, and there is evidence of cardiac involvement and myocardial injury in some patients with COVID-19.^{7–17} Given their potential cardioprotective effects, statins may possibly prevent myocardial injury and adverse cardiovascular events, particularly in patients with established cardiovascular disease.¹⁸ Second, beyond their lipid-lowering properties, statins exert various beneficial pleiotropic effects, including modulating the immune response at different levels, improving endothelial function, and decreasing oxidative stress and inflammation.^{18–21} Third, some randomised clinical trials and observational studies—but not all—have indicated that statins may be associated with less severe infection and improved outcomes in patients with viral infections.^{22–31} On the other hand, experimental studies have suggested that statins, among other drugs, may increase the expression of ACE2,^{32–34} a membrane-bound aminopeptidase expressed in the lungs, heart and other tissues that is thought to facilitate entry of SARS-CoV-2 into the cells.^{35–37} Also, case series have reported hypercholesterolaemia to be one of the most common comorbidities in patients with COVID-19.³⁸ These considerations have led to the concern that statins may confer a predisposition to more severe infection and adverse outcomes during COVID-19 infection. Taken together, the effect of statins on outcomes in patients with COVID-19 infection remains unclear.

In light of these uncertainties, it is important to assess whether statin therapy may improve the clinical course of patients with COVID-19 infection or lead to further deterioration. To address this issue, we performed a nationwide registry-based cohort study to investigate the association between recent statin exposure and the risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 infection.

METHODS

Data sources

In Denmark, all citizens are assigned a unique and personal identification number, which allows accurate linkage of nationwide administrative registries at an individual level. For this study, data from the following nationwide administrative registries were obtained: the Danish National Patient Registry, which contains data on all hospital admissions and outpatient contacts according to the International Classification of Diseases (ICD)³⁹; the Danish National Prescription Registry, which holds information on dispensing date, strength and quantity of all claimed drug prescriptions in Denmark⁴⁰; the Danish Civil Registration System, which holds information on birth date, sex and vital status (ie, whether a person is alive and a resident of Denmark, disappeared, emigrated or dead, along with the date of these events)⁴¹; and Statistics Denmark, which holds data on education, household income and marital status.^{42 43} The Danish registries are

validated, of high quality and have been described in detail previously.^{39–43}

Study population

The study population comprised all Danish citizens who were examined at a hospital, including inpatient, outpatient and emergency department visits, and had a primary or secondary diagnosis code for COVID-19 infection (ICD-10 codes: B342, B972) from 22 February 2020 until 17 May 2020. According to the Danish Ministry of Health, these codes have a positive predictive value of 99%. Comorbidity was obtained using in-hospital and outpatient diagnosis codes any time prior to diagnosis (online supplemental eTable 1 for ICD-8 and ICD-10 codes). Patients with hypertension were identified using claimed drug prescriptions as described previously.^{44 45} Pharmacotherapy at baseline was defined as claimed prescriptions within 180 days prior to diagnosis (online supplemental eTable 2 for Anatomical Therapeutic Chemical (ATC) Classification System codes). The highest level of completed education was classified in accordance with the International Standard Classification of Education. Average household income in 2018 was calculated and graded in quartiles. The duration of statin treatment prior to COVID-19 diagnosis was determined for each individual during follow-up using an algorithm based on claimed prescriptions, taking date of claimed prescriptions, dosage and packing size into account, as described previously.^{46 47}

Exposure

Exposure to statins was defined as at least one redeemed prescription of a statin (ATC code C10AA) in the 6 months prior to diagnosis.

Outcomes

The primary outcome was all-cause mortality. The secondary outcomes were (1) severe COVID-19 infection, defined as a hospital diagnosis of ‘COVID-19 severe acute respiratory syndrome’ (ICD-10 code: B972A) or admission to an intensive care unit; and (2) the composite of all-cause mortality or severe COVID-19 infection. Patients were followed from the date of diagnosis until occurrence of the outcome of interest, death, emigration or 17 May 2020, whichever came first.

Statistics

Baseline characteristics were reported as frequencies with percentages or medians with 25th–75th percentiles. Differences in baseline characteristics according to statin exposure were tested with χ^2 test for categorical variables and Mann-Whitney test for continuous variables. Cause-specific unadjusted and adjusted Cox regression models were used to compare outcomes according to statin exposure. Adjusted models included the following variables: age (modelled as a restricted cubic spline with three knots: 10th, 50th and 90th percentile), sex, ethnicity (native Danish, immigrant, descendant from immigrant), education, income, comorbidity (ie, history of ischaemic

heart disease, stroke, peripheral artery disease, diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta-blockers, calcium channel blockers, renin-angiotensin-aldosterone system inhibitors). Reported were HRs, 30-day risks of outcomes standardised to the risk factor distribution of all patients in the sample, and differences of standardised 30-day risks. For the outcome severe COVID-19 infection, the main Cox regression model was combined with a Cox regression model for the rate of the competing risk of death without severe COVID-19 infection.⁴⁸ Interactions between statin exposure and clinically relevant variables (including age categories, sex, presumed indication for statin therapy (ie, history of stroke, ischaemic heart disease, peripheral artery disease, diabetes mellitus or familial hypercholesterolaemia)) on outcomes were tested for. All statistical analyses were performed with SAS V.9.4 statistical software and R V.3.6.1 (The R Foundation).⁴⁹ The level of statistical significance was set at 5%.

To test the robustness of our findings, a number of sensitivity analyses were performed: (1) The definition of statin exposure was changed from at least one redeemed prescription of a statin in the 6 months prior to diagnosis to 3 months. (2) The risk of death among patients with severe COVID-19 infection according to statin exposure was examined. (3) Among patients with statin exposure, the risks of outcomes according to statin treatment intensity (ie, high-intensity vs moderate-intensity/low-intensity) were investigated. High-intensity statin therapy was defined as either (1) atorvastatin 40–80 mg daily, (2) rosuvastatin 20–40 mg daily or (3) simvastatin 80 mg daily. (4) Among patients with statin exposure, the risk of outcomes according to statin drug (ie, simvastatin, atorvastatin, rosuvastatin) was examined. Pravastatin was excluded from this analysis due to a low number of patients prescribed this drug. (5) The statin population was restricted to those with a treatment duration of at least 3 months.

Patient and public involvement

This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

RESULTS

In total, 4842 patients with COVID-19 infection were included in the study. Of these, 843 (17.4%) redeemed a prescription of statins within 6 months prior to diagnosis. The first patient was included on 22 February 2020 and the last patient on 17 May 2020. The median age of the study population was 54 years (25th–75th percentile,

40–72), and 47.1% were men. The mean duration of statin treatment prior to COVID-19 diagnosis was 3.6 years. The baseline characteristics of the patients in the groups of interest are summarised in [table 1](#). Patients with statin exposure were older, more often men and native Danish, had a greater prevalence of cardiovascular and non-cardiovascular comorbidities, and a higher utilisation of medication compared with those admitted with no statin exposure. The median follow-up time from the date of COVID-19 diagnosis was 44 days (25th–75th percentile, 29–56).

All-cause mortality, composite outcome and severe COVID-19 infection

Unadjusted, sex-adjusted and age-adjusted, and fully adjusted HRs for statin exposure and outcomes are shown in [figure 1](#). [Table 2](#) displays unadjusted, sex-adjusted and age-adjusted, and fully adjusted standardised 30-day absolute risks of outcomes according to statin exposure. In total, 488 (10.1%) patients died during follow-up: 177 (21.0%) in the statin group and 311 (7.8%) in the non-statin group. In the unadjusted Cox regression analysis, statin exposure was associated with a significantly higher risk of mortality compared with no statin exposure (HR 2.87 (95% CI 2.39 to 3.46)). However, when adjusting for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18)). Similarly, the standardised absolute 30-day risk of all-cause mortality was not significantly different between groups (9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%)) in the no statin and statin exposure groups, respectively; standardised absolute risk difference, -0.4% (-1.9% to 1.2%).

During follow-up, 881 (18.2%) patients experienced the composite outcome of all-cause mortality or severe COVID-19 infection: 292 (34.6%) in the statin group and 589 (14.7%) in the non-statin group. Although statin exposure was associated with a significantly higher risk of the composite outcome compared with no statin exposure in the unadjusted Cox regression analysis (HR 2.57 (95% CI 2.34 to 2.96)), statin exposure was not associated with a significantly different risk of mortality in the fully adjusted analysis (HR 1.05 (95% CI 0.89 to 1.23)). Similarly, the standardised absolute 30-day risk of the composite outcome was not significantly different between groups (17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%)) in the no statin and statin exposure groups, respectively; standardised absolute risk difference, 0.6% (-1.6% to 2.9%).

In total, 623 (12.9%) patients developed severe COVID-19 infection during follow-up: 204 (24.2%) in the statin group and 419 (10.5%) in the non-statin group. In the unadjusted Cox regression analysis, statin exposure was associated with a significantly higher risk of severe COVID-19 infection compared with no statin exposure (HR 2.41 (95% CI 2.04 to 2.85)). However, in the fully adjusted analysis, statin exposure was not associated with

Table 1 Baseline characteristics of patients with COVID-19 with and without statin exposure

	No statin exposure n=3999	Statin exposure n=843
Demographics		
Age, median (25th–75th percentile)	50 (37–65)	73 (63–79)
Age, n (%)		
<50 years	1965 (49.1)	40 (4.7)
50–70 years	1246 (31.2)	307 (36.4)
>71 years	788 (19.7)	496 (58.8)
Male, n (%)	1766 (44.2)	515 (61.1)
Ethnicity, n (%)		
Native Danish	3270 (81.8)	729 (86.5)
Immigrant	610 (15.2)	110 (13.0)
Descendant from immigrant	119 (3.0)	4 (0.5)
Socioeconomic status		
Education, n (%)		
Basic school	980 (24.5)	294 (34.9)
High school/vocational education	1427 (35.7)	369 (43.8)
Short/medium higher education	506 (12.6)	53 (6.3)
Long higher education	1086 (27.2)	127 (15.1)
Income group, n (%)		
Q1 (lowest)	987 (24.7)	223 (26.4)
Q2	922 (23.0)	289 (34.3)
Q3	1003 (25.1)	208 (24.7)
Q4 (highest)	1087 (27.2)	123 (14.6)
Comorbidities, n (%)		
Ischaemic heart disease	182 (4.6)	262 (31.1)
Stroke	95 (2.4)	119 (14.1)
Peripheral artery disease	35 (0.9)	51 (6.0)
Diabetes	188 (4.7)	230 (27.3)
Heart failure	98 (2.5)	85 (10.1)
Atrial fibrillation	206 (5.2)	144 (17.1)
Hypertension	491 (12.3)	452 (53.6)
Malignancy	345 (8.6)	147 (17.4)
Chronic kidney disease	127 (3.2)	104 (12.3)
Chronic obstructive pulmonary disease	142 (3.6)	80 (9.5)
Liver disease	95 (2.4)	18 (2.1)
Concomitant medical treatment, n (%)		
Aspirin	132 (3.3)	238 (28.2)
Oral anticoagulants	222 (5.6)	169 (20.0)
Beta-blockers	283 (7.1)	303 (35.9)
Calcium channel blockers	282 (7.1)	247 (29.3)
RAAS inhibitors	522 (13.1)	438 (52.0)
Type of statin, n (%)		

Continued

Table 1 Continued

	No statin exposure n=3999	Statin exposure n=843
Atorvastatin	N/A	426 (50.5)
Simvastatin	N/A	351 (41.7)
Rosuvastatin	N/A	57 (6.8)
Pravastatin	N/A	9 (1.0)

N/A, not applicable; RAAS, renin-angiotensin-aldosterone system inhibitors.

a significantly different risk of severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41)). Similarly, the standardised absolute 30-day risk of severe COVID-19 infection was not significantly different between groups (13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%) in the no statin and statin exposure groups, respectively; standardised absolute risk difference, 1.9% (−0.7% to 4.5%)).

Subgroup and sensitivity analyses

The results of the prespecified subgroup analyses for the primary and secondary outcomes are displayed in [table 3](#). In all subgroups, statin exposure was not associated with a significantly different risk of all-cause mortality, a composite of all-cause mortality or severe COVID-19 infection, and COVID-19 infection (p for interaction >0.23 for all subgroups).

To test the robustness of the findings, we performed a number of sensitivity analyses. (1) The definition of statin exposure was changed from as at least one redeemed prescription of a statin in the 6 months prior to diagnosis to 3 months. In total, 646 (13.3%) patients redeemed a prescription of a statin within 3 months. Among those who redeemed a statin prescription within 6 months, but not within 3 months, 82.2% redeemed a prescription of 100 tablets or more. In this analysis, statin exposure was not associated with a significantly different risk of all-cause mortality (adjusted HR 0.97 (95% CI 0.78 to 1.20); standardised absolute 30-day risk difference, −0.2% (−1.8% to 1.3%)), a composite of all-cause mortality or severe COVID-19 infection (adjusted HR 1.06 (95% CI 0.90 to 1.26); standardised absolute 30-day risk difference, 0.9% (−1.4% to 3.3%)), or severe COVID-19 infection (adjusted HR 1.18 (95% CI 0.97 to 1.45); standardised absolute 30-day risk difference, 2.3% (−0.4% to 5.1%)). (2) The risk of death among patients with severe COVID-19 infection according to statin exposure was examined. In this analysis, statin exposure was not associated with a significantly different risk of all-cause mortality (adjusted HR 0.91 (95% CI 0.65 to 1.27)). (3) Among patients with statin exposure, the risks of outcomes according to intensity of statin therapy were investigated. In total, 305 (36.2%) patients received high-intensity statin therapy. Compared with moderate-intensity/low-intensity therapy, high-intensity statin therapy was not associated with a




Figure 1 HR for all-cause mortality, a composite of severe COVID-19 infection or all-cause mortality, and severe COVID-19 infection according to statin exposure. Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic heart disease, stroke, peripheral artery disease, diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta-blockers, calcium channel blockers, renin-angiotensin-aldosterone system inhibitors).

significantly different risk of all-cause mortality (adjusted HR 1.07 (95% CI 0.77 to 1.50)), a composite of all-cause mortality or severe COVID-19 infection (adjusted HR 0.95 (95% CI 0.73 to 1.22)), or severe COVID-19 infection (adjusted HR 0.81 (95% CI 0.60 to 1.10)). (4) Among patients with statin exposure, the risks of outcomes according to statin drug were investigated. Compared with simvastatin, atorvastatin and rosuvastatin were not associated with a significantly different risk of all-cause mortality (atorvastatin: adjusted HR 0.99 (95% CI 0.72 to 1.37); rosuvastatin: adjusted HR 0.43 (95% CI 0.15 to 1.19)), a composite of all-cause mortality or severe COVID-19 infection (atorvastatin: adjusted HR 0.91 (95% CI 0.71 to 1.17); rosuvastatin: adjusted HR 0.90 (95% CI 0.53 to 1.54)), or

severe COVID-19 infection (atorvastatin: adjusted HR 0.80 (95% CI 0.60 to 1.08); rosuvastatin: adjusted HR 1.03 (95% CI 0.59 to 1.82)). (5) The statin population was restricted to those with a treatment duration of at least 3 months. Excluding patients in the statin group with a treatment duration less than 3 months, the population yielded similar findings as the main results (all-cause mortality, adjusted HR 1.00 (95% CI 0.81 to 1.24); a composite of all-cause mortality or severe infection, 1.09 (0.92 to 1.29); severe COVID-19 infection, 1.19 (0.97 to 1.47)).

Table 2 Standardised 30-day absolute risks and risk differences for all-cause mortality, a composite of severe COVID-19 infection or all-cause mortality, and severe COVID-19 infection according to statin exposure

	No statin exposure 30-day risk, % (95% CI)	Statin exposure 30-day risk, % (95% CI)	30-day risk difference, % (95% CI)
All-cause mortality			
Unadjusted	7.5 (6.6 to 8.3)	20.0 (17.4 to 22.6)	12.5 (9.8 to 15.2)
Age-adjusted and sex-adjusted	9.6 (8.4 to 10.7)	10.0 (8.7 to 11.3)	0.4 (-1.1 to 1.9)
Fully adjusted*	9.8 (8.7 to 11.0)	9.5 (8.2 to 10.8)	-0.4 (-1.9 to 1.2)
Composite outcome			
Unadjusted	14.7 (13.6 to 15.8)	34.2 (31.2 to 37.2)	19.6 (16.3 to 22.8)
Age-adjusted and sex-adjusted	17.1 (16.0 to 18.3)	19.4 (17.6 to 21.3)	2.3 (0.1 to 4.5)
Fully adjusted*	17.6 (16.4 to 18.8)	18.2 (16.4 to 20.1)	0.6 (-1.6 to 2.9)
Severe COVID-19 infection			
Unadjusted	10.8 (9.8 to 11.8)	25.6 (22.6 to 28.7)	14.9 (11.5 to 18.2)
Age-adjusted and sex-adjusted	12.7 (11.5 to 13.8)	15.8 (13.7 to 17.9)	3.2 (0.7 to 5.7)
Fully adjusted*	13.0 (11.8 to 14.2)	14.9 (12.8 to 17.1)	1.9 (-0.7 to 4.5)

*Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic heart disease, stroke, peripheral artery disease, diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta-blockers, calcium channel blockers, renin-angiotensin-aldosterone system inhibitors).

**Table 3** Fully adjusted HR for all-cause mortality, a composite of severe COVID-19 infection or all-cause mortality, and severe COVID-19 infection according to statin exposure in subgroups

	Mortality HR (95% CI)	Composite outcome HR (95% CI)	Severe COVID-19 infection HR (95% CI)
Overall	0.96 (0.78 to 1.18)	1.05 (0.89 to 1.23)	1.16 (0.95 to 1.41)
Age categories			
<50 years	N/A	0.50 (0.11 to 2.21)	0.50 (0.11 to 2.22)
50–70 years	0.55 (0.29 to 1.08)	1.00 (0.72 to 1.40)	1.06 (0.74 to 1.50)
>70 years	1.02 (0.82 to 1.28)	1.05 (0.87 to 1.28)	1.09 (0.85 to 1.41)
Sex			
Male	1.06 (0.81 to 1.37)	1.03 (0.84 to 1.26)	1.04 (0.82 to 1.33)
Female	0.78 (0.54 to 1.13)	1.07 (0.81 to 1.42)	1.39 (0.98 to 1.99)
Presumed indication for statin therapy			
Yes	0.90 (0.68 to 1.20)	1.00 (0.79 to 1.26)	1.16 (0.86 to 1.57)
No	0.98 (0.71 to 1.36)	1.03 (0.81 to 1.30)	1.07 (0.81 to 1.41)

Reference group: no statin exposure.

Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic heart disease, stroke, peripheral artery disease, diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta-blockers, calcium channel blockers, renin-angiotensin-aldosterone system inhibitors).

All p values for differences within subgroups were not statistically significant (>0.23).

N/A, not applicable.

DISCUSSION

In this Danish nationwide cohort study, we investigated the association between recent statin exposure and the risk of all-cause mortality or severe infection, individually and as a composite, in patients with COVID-19 infection. The main finding of this study was that statin exposure prior to COVID-19 diagnosis was not associated with an improvement or deterioration in the clinical course of patients with COVID-19 infection, and this was consistent across clinically relevant subgroups.

In a recent observational study using data from 21 hospitals in Hubei Province, China, Zhang *et al*² demonstrated that in-hospital use of statins was associated with improved survival among patients hospitalised with COVID-19. Specifically, the authors found a 28-day mortality risk of 5.2% and 9.4% in the statin and non-statin user groups, respectively, and that in-hospital use of statins was associated with a 42% decrease in in-hospital mortality.² Although the data may be biased by patient selection, treatment indication and residual confounding, including lack of adjustment for socioeconomic status and prehospital medication, this controversial finding merits further investigation. In addition, Farag *et al*³ performed a computer-based study and used a structure-based drug design to screen more than 2000 Food and Drug Administration-approved drugs against SARS-CoV-2 main protease enzyme substrate-binding pocket. Other than antiviral drugs, the authors also identified rosuvastatin as a drug that may be useful against SARS-CoV-2. On the other hand, other observational studies, including a meta-analysis, did not find an association between statin therapy and improved outcomes

in patients with COVID-19.^{4–6} In our nationwide cohort study including all patients with COVID-19, irrespective of hospitalisation status, we did not find any association between statin use prior to diagnosis and the risk of all-cause mortality or severe COVID-19 infection, individually and as a composite. These results were consistent across clinically relevant subgroups, including age, sex and presumed indication for statin therapy. In addition, among patients using statins, type of statin drug did not significantly modify the risk of outcomes, although there was a trend towards a lower risk of all-cause mortality with rosuvastatin. Further studies are warranted to establish whether rosuvastatin may improve outcomes in patients with COVID-19 infection. Taken together, our study does not provide evidence of a beneficial effect of statin exposure prior to COVID-19 diagnosis.

Several hypotheses have been proposed in relation to the role of statin therapy in patients with COVID-19. It has been proposed that statins may improve the clinical course in patients with COVID-19, and several mechanisms by which statins exert their potential beneficial effects have been proposed. For example, reports of cardiac involvement during the course of the infection, particularly in severe cases, have emerged,^{7–17} and it has been hypothesised that statins, at least to some extent, may prevent or decrease the likelihood of myocardial injury and cardiovascular events.¹⁸ Further, statins may modulate the immune response, improve endothelial function, and decrease oxidative stress and inflammation and thereby predispose to less severe infection and better outcomes.^{18–21} Data on such effects of statins in humans, however, are conflicting. While some randomised trials

and observational studies have demonstrated possible benefits of statins in reducing mortality and improving the clinical course of patients with severe infections, particularly viral infections, others have not found any beneficial effects of statins in this setting.^{22–31} On the other hand, preclinical studies have suggested that statins upregulate the expression of ACE2, an enzyme thought to facilitate entry of SARS-CoV-2 into the cells, although this hypothesis has not been proven in humans.^{32–34} Moreover, hypercholesterolaemia has been reported to be one of the most common comorbidities in patients with COVID-19, although the majority of these case series did not report data on medication, including statins.³⁸ These considerations had led to the hypothesis that statins confer a greater risk of more severe infection and adverse outcomes during COVID-19 infection. In light of these concerns, it is reassuring that statins were not associated with a deterioration in the clinical course of these patients in our study. Taken together, our findings do not support discontinuation of statin therapy in patients with an indication for statins. However, it is important to emphasise the inherent limitations of observational studies, including residual confounding, confounding by indication and inadequate assessment of causal inference. There is, therefore, a need for further studies to establish the role of statins in patients with COVID-19 with and without an indication for statin therapy. Several randomised clinical trials have been initiated to assess this clinically relevant issue, and the results from these trials are anticipated.^{50–53}

Another potential concern with statins during COVID-19 infection is liver injury. Reports of liver injury during the course of the infection, particularly in severe cases, have emerged.^{54–56} Although statins are generally considered to be safe and well tolerated, in rare cases, these medications may also induce liver injury.⁵⁷ Consequently, the European Society of Cardiology guidelines for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic recommend withholding statin therapy temporarily in patients with COVID-19 with increased liver enzymes.⁵⁸ Whether statin therapy confers an increased risk of liver injury and subsequent adverse outcomes during COVID-19 infection has not been established. Our study did not allow for a direct assessment of this issue due to lack of data on in-hospital medication and laboratory findings. Nevertheless, it is reassuring that statin exposure prior to diagnosis was not associated with an increased risk of worse outcomes in patients with COVID-19. Further studies, preferably randomised controlled trials, are needed to clarify the association between statin therapy and liver injury on subsequent outcomes during COVID-19 infection.

Strengths and limitations

The main strength of this study is the completeness of data from nationwide administrative registries. The Danish healthcare system, funded by taxes, provides equal access to healthcare services for all residents regardless of

socioeconomic or insurance status. In Denmark, statins can be purchased only through prescription. Due to partial reimbursement of drug expenses by the Danish healthcare system, pharmacies are required to register all redeemed prescriptions ensuring complete and accurate registration. The findings of this study should be viewed in the context of a number of limitations. The observational nature of this study precludes the assessment of cause–effect relationships; thus, only associations are reported. Residual confounding cannot be excluded despite adjustment for potential confounders, and it is likely that these adjustments were not sufficient to even out the differences between the groups. For example, mounting evidence suggests that patients with COVID-19 may develop clinically significant coagulopathy with fatal thromboembolic complications,^{59–61} and more statin users were treated with aspirin and oral anticoagulants compared with non-statin users. Although we attempted to minimise the impact of these differences by adjusting for concomitant medication, including aspirin and oral anticoagulants, in the fully adjusted analyses, we cannot exclude the possibility that these differences may have had an impact on the association between statin use and outcomes. In addition, confounding by indication cannot be omitted in pharmacoepidemiological studies despite our attempt to minimise the impact of this limitation by performing several subgroup analyses (eg, patients with or without a presumed indication for statin therapy). We did not have laboratory data to confirm a positive swab test for COVID-19. However, coding of both tested individuals with tentative diagnosis codes and those with positive swabs with definite diagnosis codes have been and are systematically performed in Denmark, and the Danish Ministry of Health have indicated a positive predictive value of 99% of these codes. Compared with the official COVID-19 case numbers in Denmark, this study included fewer cases because ICD-10 codes capture only those patients who were diagnosed in the hospital system (inpatient, outpatient or emergency department visits) and not in dedicated COVID-19 diagnostic kiosks. It is therefore possible that some patients with no or few symptoms may not have been captured by our ICD-10 codes. The outcomes examined in this study were clinically relevant ‘hard’ endpoints. Although it would have been interesting to examine the association between recent statin exposure and symptom improvement in patients with COVID-19, data on symptoms were not available. In addition, due to lack of data on in-hospital medication, we were not able to investigate the impact of in-hospital statin therapy on outcomes. Likewise, data on statin treatment (dis)continuation after the COVID-19 diagnosis were not available, although it was encouraged to continue statin treatment at the Danish hospitals. Exposure to statins was defined by redeemed prescriptions in the 6 months prior to diagnosis, although similar results were yielded when restricting this definition from 6 months to 3 months. It is possible that some patients may discontinue statin treatment prior to diagnosis due to early symptoms of COVID-19 infection.

However, we believe that this number is likely to be low, as the mainstream media and professional medical societies have not raised questions about statin treatment in the setting of COVID-19 to the same extent as, for example, ACE inhibitors/angiotensin receptor blocker treatment. Finally, data on whether patients were prescribed statins for primary or secondary prevention were not available. However, restricting the study population to patients with a presumed indication for statin therapy (ie, history of stroke, ischaemic heart disease, peripheral artery disease, diabetes mellitus or familial hypercholesterolaemia) yielded similar findings as the main analyses.

CONCLUSIONS

In this Danish nationwide cohort study, recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection. Hence, our study does not suggest benefit or harm of statin therapy in patients with COVID-19. However, further studies are needed to establish the role of statins in patients with COVID-19 with and without an indication for statin therapy. Several randomised clinical trials have been initiated to assess this clinically relevant issue in patients with COVID-19, and the results from these trials are anticipated.

Author affiliations

¹Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

²The Danish Heart Foundation, Copenhagen, Denmark

³Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark

⁴Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark

⁵Departments of Cardiology, North Denmark Regional Hospital and Aalborg University Hospital, Aalborg, Denmark

⁶Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark

⁷Department of Clinical Research and Cardiology, Nordsjællands Hospital, Hillerød, Denmark

Contributors JHB and ELF had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: JHB, ELF, LK. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: JHB. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: JHB.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval In Denmark registry-based studies that are conducted for the sole purpose of statistics and scientific research do not require ethical approval or informed consent by law. However, the study is approved by the data responsible institute (Capital Region of Denmark, approval number: P-2019-191) in accordance with the General Data Protection Regulation.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. Data for this study are derived from Statistics Denmark. By law, these data are not allowed to be shared and therefore data cannot be made available to other researchers.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content

includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Jawad Haider Butt <http://orcid.org/0000-0002-7380-4144>

REFERENCES

- 1 Organisation WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. WHO Dir. Gen. speeches. 2020;:4. Available: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020> [Accessed 17 Apr 2020].
- 2 Zhang X-J, Qin J-J, Cheng X, *et al*. In-Hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. *Cell Metab* 2020;32:176-87.
- 3 Farag A, Wang P, Boys I, *et al*. Identification of atovaquone, ouabain and mebendazole as FDA approved drugs Targeting SARS-CoV-2 (version 4). *ChemRxiv* 2020. doi:10.26434/chemrxiv.12003930.v4
- 4 De Spiegeleer A, Bronselaer A, Teo JT, *et al*. The effects of Arbs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. *J Am Med Dir Assoc* 2020;21:909-14.
- 5 Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. *Diabetes Metab Syndr* 2020;14:1613-5.
- 6 Grasselli G, Greco M, Zanella A, *et al*. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med* 2020;180:1345-11.
- 7 Inciardi RM, Lupi L, Zaccone G, *et al*. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 2020;5:819.
- 8 Whitlock R, Healey JS, Connolly SJ, *et al*. Predictors of early and late stroke following cardiac surgery. *CMAJ* 2014;186:905-11.
- 9 Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061-9.
- 10 Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- 11 Shi S, Qin M, Shen B, *et al*. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA Cardiol* 2020;5:802.
- 12 Shi S, Qin M, Cai Y, *et al*. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. *Eur Heart J* 2020;41:2070-9.
- 13 Zhou F, Yu T, Du R, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054-62.
- 14 Guan W-J, Ni Z-Y, Hu Y, *et al*. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-20.
- 15 Zheng Y-Y, Ma Y-T, Zhang J-Y, *et al*. COVID-19 and the cardiovascular system. *Nat Rev Cardiol* 2020;17:259-60.
- 16 Yang J, Zheng Y, Gou X, *et al*. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. *Int J Infect Dis* 2020;94:91-5.
- 17 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239-42.
- 18 Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. *Circ Res* 2017;120:229-43.
- 19 Zeiser R. Immune modulatory effects of statins. *Immunology* 2018;154:69-75.
- 20 Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. *Nat Rev Immunol* 2019;19:104-17.
- 21 Aronov DM. [Pleiotropic effects of statins]. *Kardiologija* 2008;48:60-8.
- 22 Frost FJ, Petersen H, Tollestrup K, *et al*. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. *Chest* 2007;131:1006-12.

- 23 Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. *BMJ* 2011;342:d1642.
- 24 Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. *J Infect Dis* 2012;205:13–19.
- 25 Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. *PLoS One* 2009;4:e8087.
- 26 Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during Winters 1998-1999 to 2005-2006. *Epidemiol Infect* 2010;138:1281–8.
- 27 Makris D, Manoulakas E, Komnos A, et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. *Crit Care Med* 2011;39:2440–6.
- 28 Papazian L, Roch A, Charles P-E, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. *JAMA* 2013;310:1692–700.
- 29 Yuan S. Statins may decrease the fatality rate of middle East respiratory syndrome infection. *MBio* 2015;6:e01120.
- 30 Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. *PLoS One* 2011;6:e18120.
- 31 Pertzov B, Eliakim-Raz N, Atamna H, et al. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - A systematic review and meta-analysis. *Clin Microbiol Infect* 2019;25:280–9.
- 32 Tikoo K, Patel G, Kumar S, et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. *Biochem Pharmacol* 2015;93:343–51.
- 33 Li Y-H, Wang Q-X, Zhou J-W, et al. Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats. *J Geriatr Cardiol* 2013;10:151–8.
- 34 Shin YH, Min JJ, Lee J-H, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. *Heart Vessels* 2017;32:618–27.
- 35 Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270–3.
- 36 Li W, Moore MJ, Vasilieva N, et al. Angiotensin-Converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003;426:450–4.
- 37 Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev* 2006;86:747–803.
- 38 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020;323:1574–81.
- 39 Lyng E, Sandegaard JL, Rebolj M. The Danish national patient register. *Scand J Public Health* 2011;39:30–3.
- 40 Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scand J Public Health* 2011;39:38–41.
- 41 Pedersen CB. The Danish civil registration system. *Scand J Public Health* 2011;39:22–5.
- 42 Jensen VM, Rasmussen AW. Danish education registers. *Scand J Public Health* 2011;39:91–4.
- 43 Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public Health* 2011;39:103–5.
- 44 Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. *Circulation* 2008;117:1945–54.
- 45 Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ* 2011;342:d124.
- 46 Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. *Circulation* 2006;113:2906–13.
- 47 Schjerning Olsen A-M, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. *JAMA* 2015;313:805–14.
- 48 Ozenne BMH, Scheike TH, Staerk L, et al. On the estimation of average treatment effects with right-censored time to event outcome and competing risks. *Biom J* 2020;62:751–63.
- 49 R Core Team. R core team 2014 R: a language and environment for statistical computing. R foundation for statistical computing. Available: <https://www.R-project.org/>. 2015
- 50 Nct. Study of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19, 2020. Available: <https://clinicaltrials.gov/show/NCT04348695>
- 51 NCT04343001. Coronavirus Response - Active Support for Hospitalised Covid-19 Patients, 2020. Available: <https://clinicaltrials.gov/show/NCT04343001>
- 52 NCT04333407. Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial, 2020. Available: <https://clinicaltrials.gov/show/NCT04333407>
- 53 Clinical trials. Atorvastatin in COVID-19 (STATCO19). Available: <https://clinicaltrials.gov/ct2/show/NCT04380402>
- 54 Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. *Liver Int* 2020;40:998–1004.
- 55 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020;395:507–13.
- 56 Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-Related liver functional abnormality. *Clin Gastroenterol Hepatol* 2020;18:1561–6.
- 57 Jose J. Statins and its hepatic effects: newer data, implications, and changing recommendations. *J Pharm Bioallied Sci* 2016;8:23–8.
- 58 European Society of cardiology. ESC guidance for the diagnosis and management of cv disease during the COVID-19 pandemic. *Eur Heart J* 2020;1–115.
- 59 Oxley TJ, Mocco J, Majidi S, et al. Large-Vessel stroke as a presenting feature of covid-19 in the young. *N Engl J Med* 2020;382:e60.
- 60 Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and stroke in a new York healthcare system. *Stroke* 2020;51:2002–11.
- 61 Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis* 2020;50:54–67.

Online-only supplement

Association Between Statin Use and Outcomes in Patients with Coronavirus Disease 2019 (Covid-19): A Nationwide Cohort Study

Jawad H. Butt, MD; Thomas A. Gerds, Dr.rer.nat; Morten Schou, MD, DMSc;
Kristian Kragholm, MD, PhD; Matthew Phelps, PhD; Eva Havers-Borgersen, MB;
Adelina Yafasova, MB; Gunnar Gislason, MD, PhD; Christian Torp-Pedersen, MD, DMSc;
Lars Køber, MD, DMSc; Emil L. Fosbøl, MD, PhD

Contents

eTable 1. ICD-8 and -10 codes.....	2
eTable 2. ATC classification codes.....	3

eTable 1. ICD-8 and -10 codes

Comorbidity or outcomes	ICD-8 and ICD-10 codes
Ischemic heart disease	ICD-10: I20-I25 ICD-8: 410-414
Stroke	ICD-10: I60, I61, I63, I64 ICD-8: 430, 431, 433, 434
Peripheral artery disease	ICD-10: I70, I74 ICD-8: 440, 444
Diabetes	ICD-10: E10-E14 ICD-8: 250
Heart failure	ICD-10: I42, I50, J81, I110, I130, I132 ICD-8: 425, 428, 4270, 4271
Atrial fibrillation	ICD-10: I48 ICD-8: 42793, 42794
Malignancy	ICD-10: C00-C97 (if not C44) ICD-8: 140-209 (if not 173)
Chronic kidney disease	ICD-10: E102, E112, E132, E142, I120, N02-N08, N11, N12, N14, N18, N19, N26, N158-N160, N162-N164, N168, M300, M313, M319, M321B, Q612, Q613, Q615, Q619, T858, T859, Z992 ICD-8: 403, 404, 581-584, 25002, 40039, 59009, 59320, 75310, 75311, 75319
Chronic obstructive pulmonary disease	ICD-10: J42-J44 ICD-8: 490-492
Liver disease	ICD-10: B15-B19, K70-K77, C22, I982, Z944, D684C, Q618A ICD-8: 070, 155, 571-573

ICD, International Classification of Diseases

eTable 2. ATC classification codes

Pharmacotherapy	ATC codes
Atorvastatin	C10AA05
Simvastatin	C10AA01
Rosuvastatin	C10AA07
Pravastatin	C10AA03
Aspirin	B01AC06
Oral anticoagulants	B01AA03, B01AA04, B01AE07, B01AF01, B01AF02
Beta-blockers	C07, C09BX
Calcium channel blockers	C08, C07F, C09BB, C09DB
Renin-angiotensin-system inhibitors	C09
Vasodilator drugs	C02DB, C02DD, C02DG
Antiadrenergic drugs	C02A, C02B, C02C
Thiazides	C03A, C07B, C07D, C09XA52, C03EA01
Loop diuretics	C03C, C03EB01, C03EB02
Spirolactone	C03DA01

ATC, Anatomical Therapeutic Chemical; ADP, adenosine diphosphate